Supplementary table: Eliminating drug target interference withspecific antibody or its F(ab?)2 fragment inthe bridging immunogenicity assay

Background: DB-1003 is a humanized anti-IgE monoclonal antibody with higher affinity than omalizumab. In the affinity capture elution (ACE)-based bridging electrochemiluminescent immunoassay (ECLIA) for antibodies to DB-1003, monkey serum IgE caused false-positive results. Materials & methods: The target specific antibody or its F(ab?)2 fragment was used to mitigate drug target interference in an ACE-based bridging ECLIA for the detection of anti-DB-1003 antibodies. Results: The sensitivity of the developed assay was at least 100 ng/ml. When the ADA concentration was 250 ng/ml, the assay tolerated at least 20.0 μg/ml of the monkey IgE. Conclusion: Incorporating the target-specific antibody or its F(ab?)2 mfragment can overcome the interference from monkey serum IgE in ACE-based bridging ECLIA for anti- DB-1003 antibody detection.